Last reviewed 2026-05-14 · How we verify

Merck and Company's MMRII

GlaxoSmithKline · Phase 3 active Biologic

Merck and Company's MMRII is a Live attenuated vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of measles, mumps, and rubella in children and adults.

M-M-R II is a live attenuated vaccine that stimulates immune response against measles, mumps, and rubella viruses.

M-M-R II is a live attenuated vaccine that stimulates immune response against measles, mumps, and rubella viruses. Used for Prevention of measles, mumps, and rubella in children and adults.

At a glance

Generic name	Merck and Company's MMRII
Sponsor	GlaxoSmithKline
Drug class	Live attenuated vaccine
Modality	Biologic
Therapeutic area	Immunology / Infectious Disease
Phase	Phase 3

Mechanism of action

The vaccine contains weakened (attenuated) strains of measles, mumps, and rubella viruses that replicate in the body without causing disease, triggering both humoral and cell-mediated immune responses. This results in the production of antibodies and memory immune cells that protect against infection with wild-type viruses. The vaccine is typically administered as two doses to achieve durable immunity against all three viral diseases.

Approved indications

Prevention of measles, mumps, and rubella in children and adults

Common side effects

Fever
Rash
Parotitis (mumps-like symptoms)
Arthralgia/arthritis
Thrombocytopenia

Key clinical trials

Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Merck and Company's MMRII CI brief — competitive landscape report
Merck and Company's MMRII updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about Merck and Company's MMRII

What is Merck and Company's MMRII?

Merck and Company's MMRII is a Live attenuated vaccine drug developed by GlaxoSmithKline, indicated for Prevention of measles, mumps, and rubella in children and adults.

How does Merck and Company's MMRII work?

M-M-R II is a live attenuated vaccine that stimulates immune response against measles, mumps, and rubella viruses.

What is Merck and Company's MMRII used for?

Merck and Company's MMRII is indicated for Prevention of measles, mumps, and rubella in children and adults.

Who makes Merck and Company's MMRII?

Merck and Company's MMRII is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is Merck and Company's MMRII in?

Merck and Company's MMRII belongs to the Live attenuated vaccine class. See all Live attenuated vaccine drugs at /class/live-attenuated-vaccine.

What development phase is Merck and Company's MMRII in?

Merck and Company's MMRII is in Phase 3.

What are the side effects of Merck and Company's MMRII?

Common side effects of Merck and Company's MMRII include Fever, Rash, Parotitis (mumps-like symptoms), Arthralgia/arthritis, Thrombocytopenia.

Drug class: All Live attenuated vaccine drugs
Manufacturer: GlaxoSmithKline — full pipeline
Therapeutic area: All drugs in Immunology / Infectious Disease
Indication: Drugs for Prevention of measles, mumps, and rubella in children and adults
Compare: Merck and Company's MMRII vs similar drugs
Pricing: Merck and Company's MMRII cost, discount & access